Psychosis & schizophrenia
Do omega-3s improve psychosis symptoms or prevent transition to psychosis?
An updated meta-analysis did not support the early promise of omega-3 for schizophrenia symptoms or prevention in people at ultra-high risk. These are distinct clinical questions.
Updated September 24, 2026 · Editorial attribution: PV Griscom, M.Sc. · Independent clinical review pending
The question behind the headline
Clinical trials spanning established psychosis and populations at increased risk.
What the finding does—and doesn’t—tell us
An early positive small trial can be overturned by larger evidence. Omega-3 should not replace specialist assessment or established treatment.
Read the underlying research.
Selected sources, not an exhaustive reference list. Research record or abstract screening only; full-text efficacy appraisal is pending. Source publication dates may precede this page’s update date.
Three questions to take forward
- Was the study population similar to the person or situation I have in mind?
- Did it measure an outcome people feel or experience, or only a laboratory marker?
- How do formulation, usual care, absolute benefit and adverse effects change the interpretation?
Study doses describe experiments; they are not personal dosing advice. Explore safety and limitations ↗